| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8279f16bdfa9a8944aef3d330f8d523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a056028050ba7dd8126057a1f425630a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84bae1e2d3c3a33be047241742fdfeb8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e14df5c297ab0465c3d9ef25b667e990 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 |
| filingDate |
1997-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fc4a7c0ca0e4b2aa9905653bad900d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c697ebac095626ff92165862a3e2333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c01a88a8070843565e624fa6bb22c83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a231cde27115b308b78b7e78d5fc539f |
| publicationDate |
1998-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9806263-A1 |
| titleOfInvention |
Programmed cell death and ich-3 |
| abstract |
This invention relates to modulation of programmed cell death. It also relates to transgenic non-human animals comprising a disrupted Ich-3 gene and methods of making these animals. The Ich-3 mutant animals exhibit resistance to septic shock and defects in folliculogenesis. This invention also relates to methods of using the transgenic animals to screen for compounds to treat septic shock and defective folliculogenesis. Moreover, this invention also relates to methods of treating septic shock in normal individuals by inhibiting ICH-3. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9963097-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7323616-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9963097-A2 |
| priorityDate |
1996-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |